|Bid||0.9567 x 1300|
|Ask||1.0300 x 800|
|Day's Range||0.9567 - 1.0100|
|52 Week Range||0.7100 - 3.4400|
|Beta (3Y Monthly)||3.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize...
The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...